GPT and Cirrhosis: Subjects in the validation cohort (n = 467) showed a higher proportion of cirrhosis (9.4% (44/467) vs. 6.4% (171/2666)), higher median LS value (6.5 vs. 5.9 kPa), higher AST levels (47 vs. 33 IU/L) and higher alanine aminotransferase levels (57 vs. 41 IU/L) compared to those in the training cohort (all p < 0.05) (Table S1).